Edition:
United Kingdom

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

9.47USD
16 Feb 2018
Change (% chg)

$0.07 (+0.74%)
Prev Close
$9.40
Open
$9.42
Day's High
$9.58
Day's Low
$9.35
Volume
21,816
Avg. Vol
40,509
52-wk High
$10.80
52-wk Low
$5.45

Chart for

About

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $404.27
Shares Outstanding(Mil.): 48.71
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Chemocentryx Secures Up To $100 Million In New Capital Commitments

* CHEMOCENTRYX SECURES UP TO $100 MILLION IN NEW CAPITAL COMMITMENTS

04 Jan 2018

BRIEF-ChemoCentryx Says EMA Accepts Vasculitis Drug Avacopan For Conditional Review

* AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-Chemocentryx reports Q3 revenue $9.0 million

* Chemocentryx reports third quarter 2017 financial results and recent highlights

07 Nov 2017

Earnings vs. Estimates